A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Vaccines, sponsored by Pfizer. Completed at 2 sites in Gambia. Open to participants aged 42 Days to 70 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-13.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will compare the immune responses of the infants who have been given 13vPnC in the mutidose vial formulation to the immune reponses of the infants who have been given 13vPnC in the single-dose syringe formulation.
It will also evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in all infants who are vaccinated.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
Biological: 13-valent pneumococcal conjugate vaccine
Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL
Biological: 13-valent pneumococcal conjugate vaccine
Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here "n"= participants with valid and determinate IgG concentration to the given serotype.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series for Each Vaccine Group
Antibody GMC for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations. Here "n"= participants with valid and determinate IgG concentration to the given serotype.
Time frame: 1 month after the infant series
Number of Participants Reporting Local Reaction Within 5 Days After Dose 1 in MDV and SDS Group
Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 5 days after Dose 1(Day 2 to Day 6) of the infant series
Number of Participants Reporting Local Reaction Within 5 Days After Dose 2 in MDV and SDS Group
Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 5 days after Dose 2 (Day 2 to Day 6) of the infant series
Number of Participants Reporting Local Reaction Within 5 Days After Dose 3 in MDV and SDS Group
Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 5 days after Dose 3 (Day 2 to Day 6) of the infant series
Number of Participants Reporting Systemic Events Within 5 Days After Dose 1 in MDV and SDS Group
Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 5 days after Dose 1 (Day 2 to Day 6) of infant series
Number of Participants Reporting Systemic Events Within 5 Days After Dose 2 in MDV and SDS Group
Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 5 days after Dose 2 (Day 2 to Day 6) of infant series
Number of Participants Reporting Systemic Events Within 5 Days After Dose 3 in MDV and SDS Group
Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 5 days after Dose 3 (Day 2 to Day 6) of infant series
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Infant Series
An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 to 42 days after last dose that were absent before treatment or that worsened relative to pretreatment state
Time frame: Dose 1 up to 28 to 42 days after dose 3
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Prior to Dose 1
An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Adverse events were also reported in participants who provided consent but were not randomized in this study. The data of these participants has been reported under 'Screened Only' arm.
Time frame: Informed consent up to Dose 1
Percentage of Participants Achieving a Serotype-Specific Opsonophagocytic Activity (OPA) Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series
Percentage of participants achieving OPA Titer \>= lower limit of quantitation (LLOQ) along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here "n"= Number of participants with an antibody titer ≥ LLOQ for the given serotype.
Time frame: 1 month after the infant series
Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series
Antibody geometric mean titers as measured by OPA assay for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMTs were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. Here "n"= participants evaluable =specified category.
Time frame: 1 month after the infant series
| Milestone | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Started | 250 | 250 |
| Vaccinated dose 1 | 250 | 250 |
| Vaccinated dose 2 | 249 | 248 |
| Vaccinated dose 3 | 247 | 244 |
| Completed | 245 | 244 |
| Not completed | 5 | 6 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: No longer met eligibility criteria | 1 | 1 |
| Withdrew: Death | 1 | 0 |
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here "n"= participants with valid and determinate IgG concentration to the given serotype.
| percentage of participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Serotype 1 (n=245,244) | 99.2 (97.1 to 99.9) | 100.0 (98.5 to 100.0) |
| Serotype 3 (n=245,243) | 98.8 (96.5 to 99.7) | 99.6 (97.7 to 100.0) |
| Serotype 4 (n=245,244) | 99.6 (97.7 to 100.0) | 99.6 (97.7 to 100.0) |
| Serotype 5 (n=245,244) | 95.9 (92.6 to 98.0) | 97.1 (94.2 to 98.8) |
| Serotype 6A (n=243,244) | 96.3 (93.1 to 98.3) | 97.5 (94.7 to 99.1) |
| Serotype 6B (n=245,244) | 95.1 (91.6 to 97.4) | 95.1 (91.6 to 97.4) |
| Serotype 7F (n=245,244) | 99.6 (97.7 to 100.0) | 100.0 (98.5 to 100.0) |
| Serotype 9V (n=245,244) | 98.0 (95.3 to 99.3) | 98.4 (95.9 to 99.6) |
| Serotype 14 (n=245,244) | 97.6 (94.7 to 99.1) | 98.4 (95.9 to 99.6) |
| Serotype 18C (n=245,244) | 99.2 (97.1 to 99.9) | 98.0 (95.3 to 99.3) |
| Serotype 19A (n=245,244) | 99.6 (97.7 to 100.0) | 98.8 (96.4 to 99.7) |
| Serotype 19F (n=245,244) | 96.7 (93.7 to 98.6) | 97.1 (94.2 to 98.8) |
| Serotype 23F (n=245,244) | 95.9 (92.6 to 98.0) | 95.9 (92.6 to 98.0) |
Antibody GMC for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations. Here "n"= participants with valid and determinate IgG concentration to the given serotype.
| microgram per milliliter (mcg/mL) | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Serotype 1 (n=245,244) | 4.59 (4.11 to 5.12) | 4.45 (4.01 to 4.93) |
| Serotype 3 (n=245,243) | 1.38 (1.29 to 1.49) | 1.74 (1.62 to 1.87) |
| Serotype 4 (n=245,244) | 5.30 (4.84 to 5.81) | 5.28 (4.76 to 5.85) |
| Serotype 5 (n=245,244) | 2.00 (1.79 to 2.22) | 1.98 (1.79 to 2.20) |
| Serotype 6A (n=243,244) | 2.25 (2.02 to 2.50) | 2.19 (1.96 to 2.44) |
| Serotype 6B (n=245,244) | 3.42 (2.91 to 4.02) | 3.24 (2.77 to 3.78) |
| Serotype 7F (n=245,244) | 3.92 (3.59 to 4.27) | 4.18 (3.83 to 4.55) |
| Serotype 9V (n=245,244) | 2.83 (2.56 to 3.13) | 2.75 (2.49 to 3.04) |
| Serotype 14 (n=245,244) | 4.78 (4.06 to 5.63) | 4.96 (4.27 to 5.77) |
| Serotype 18C (n=245,244) | 3.47 (3.17 to 3.79) | 2.72 (2.46 to 3.00) |
| Serotype 19A (n=245,244) | 6.49 (5.70 to 7.38) | 6.44 (5.66 to 7.32) |
| Serotype 19F (n=245,244) | 5.19 (4.59 to 5.86) | 5.00 (4.43 to 5.63) |
| Serotype 23F (n=245,244) | 2.61 (2.30 to 2.97) | 2.17 (1.92 to 2.46) |
Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.
| participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Redness: Any | 1 | 0 |
| Redness: Mild | 1 | 0 |
| Redness: Moderate | 0 | 0 |
| Redness: Severe | 0 | 0 |
| Swelling: Any | 1 | 0 |
| Swelling: Mild | 1 | 0 |
| Swelling: Moderate | 0 | 0 |
| Swelling: Severe | 0 | 0 |
| Tenderness: Any | 42 | 47 |
| Tenderness: Mild | 32 | 37 |
| Tenderness: Moderate | 13 | 14 |
| Tenderness: Severe | 0 | 0 |
Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.
| participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Redness: Any (n=247, 247) | 2 | 0 |
| Redness: Mild (n=247, 247) | 2 | 0 |
| Redness: Moderate (n=247, 247) | 0 | 0 |
| Redness: Severe (n=247, 247) | 0 | 0 |
| Swelling: Any (n=247, 247) | 2 | 0 |
| Swelling: Mild (n=247, 247) | 2 | 0 |
| Swelling: Moderate (n=247, 247) | 1 | 0 |
| Swelling: Severe (n=247, 247) | 0 | 0 |
| Tenderness: Any (n=248, 247) | 34 | 32 |
| Tenderness: Mild (n=248, 247) | 27 | 28 |
| Tenderness: Moderate (n=247, 247) | 7 | 5 |
| Tenderness: Severe (n=247, 247) | 0 | 0 |
Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.
| participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Redness: Any | 0 | 0 |
| Redness: Mild | 0 | 0 |
| Redness: Moderate | 0 | 0 |
| Redness: Severe | 0 | 0 |
| Swelling: Any | 0 | 0 |
| Swelling: Mild | 0 | 0 |
| Swelling: Moderate | 0 | 0 |
| Swelling: Severe | 0 | 0 |
| Tenderness: Any | 37 | 35 |
| Tenderness: Mild | 30 | 32 |
| Tenderness: Moderate | 9 | 4 |
| Tenderness: Severe | 0 | 0 |
Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.
| participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Fever: >=38.0 degree C (n=248, 250) | 9 | 7 |
| Fever: >=38.0 but <=39.0 degrees C (n=248, 250) | 9 | 7 |
| Fever: >39.0 but <=40.0 degrees C (n=248, 250) | 0 | 0 |
| Fever: >40.0 degrees C (n=248, 250) | 0 | 0 |
| Decreased appetite: Any (n=248, 250) | 17 | 26 |
| Decreased appetite: Moderate (n=248, 250) | 17 | 26 |
| Decreased appetite: Severe (n=248, 250) | 0 | 0 |
| Irritability: Any (n=249, 250) | 103 | 93 |
| Irritability: Mild (n=249, 250) | 86 | 77 |
| Irritability: Moderate (n=248, 250) | 19 | 17 |
| Irritability: Severe (n=248, 250) | 0 | 0 |
| Increased sleep: Any (n=248, 250) | 16 | 14 |
| Increased sleep: Mild (n=248, 250) | 11 | 10 |
| Increased sleep: Moderate (n=248, 250) | 6 | 4 |
| Increased sleep: Severe (n=248, 250) | 0 | 0 |
| Use of antipyretic medication (n=248, 250) | 55 | 58 |
Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.
| participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Fever: >=38.0 degree C (n=247, 247) | 7 | 7 |
| Fever: >=38.0 but <=39.0 degrees C (n=247, 247) | 7 | 7 |
| Fever: >39.0 but <=40.0 degrees C (n=247, 247) | 1 | 0 |
| Fever: >40.0 degrees C (n=247, 247) | 0 | 0 |
| Decreased appetite: Any(n=247, 247) | 28 | 18 |
| Decreased appetite: Moderate (n=247, 247) | 28 | 18 |
| Decreased appetite: Severe (n=247, 247) | 0 | 0 |
| Irritability: Any (n=248, 247) | 93 | 83 |
| Irritability: Mild (n=248, 247) | 75 | 67 |
| Irritability: Moderate (n=247, 247) | 23 | 17 |
| Irritability: Severe (n=247, 247) | 0 | 3 |
| Increased sleep: Any (n=247, 247) | 24 | 14 |
| Increased sleep: Mild (n=247, 247) | 20 | 12 |
| Increased sleep: Moderate (n=247, 247) | 4 | 1 |
| Increased sleep: Severe (n=247, 247) | 0 | 1 |
| Use of antipyretic medication (n=248, 247) | 46 | 43 |
Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.
| participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Fever: >=38.0 degree C (n=246, 241) | 3 | 8 |
| Fever: >=38.0 but <=39.0 degrees C (n=246, 241) | 3 | 7 |
| Fever: >39.0 but <=40.0 degrees C (n=246, 241) | 0 | 1 |
| Fever: >40.0 degrees C (n=246, 241) | 0 | 0 |
| Decreased appetite: Any (n=246, 242) | 24 | 20 |
| Decreased appetite: Moderate (n=246, 242) | 24 | 19 |
| Decreased appetite: Severe (n=246, 241) | 0 | 1 |
| Irritability: Any (n=246, 243) | 83 | 92 |
| Irritability: Mild (n=246, 242) | 71 | 74 |
| Irritability: Moderate (n=246, 242) | 15 | 18 |
| Irritability: Severe (n=246, 241) | 1 | 5 |
| Increased sleep: Any (n=246, 241) | 12 | 12 |
| Increased sleep: Mild (n=246, 241) | 10 | 11 |
| Increased sleep: Moderate (n=246, 241) | 2 | 1 |
| Increased sleep: Severe (n=246, 241) | 1 | 0 |
| Use of antipyretic medication (n=246, 241) | 34 | 36 |
An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 to 42 days after last dose that were absent before treatment or that worsened relative to pretreatment state
| participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| AEs | 123 | 127 |
| SAEs | 1 | 0 |
An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Adverse events were also reported in participants who provided consent but were not randomized in this study. The data of these participants has been reported under 'Screened Only' arm.
| participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) | Screened Only |
|---|---|---|---|
| AEs | 2 | 0 | 9 |
| SAEs | 0 | 0 | 0 |
Percentage of participants achieving OPA Titer \>= lower limit of quantitation (LLOQ) along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here "n"= Number of participants with an antibody titer ≥ LLOQ for the given serotype.
| percentage of participants | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Serotype 1 (n=159,160) | 71.7 (64.0 to 78.5) | 79.4 (72.3 to 85.4) |
| Serotype 3 (n=160,160) | 98.8 (95.6 to 99.8) | 100.0 (97.7 to 100.0) |
| Serotype 4 (n=159,159) | 100.0 (97.7 to 100.0) | 100.0 (97.7 to 100.0) |
| Serotype 5 (n=160,159) | 83.1 (76.4 to 88.6) | 85.5 (79.1 to 90.6) |
| Serotype 6A (n=160,160) | 99.4 (96.6 to 100.0) | 99.4 (96.6 to 100.0) |
| Serotype 6B (n=156,155) | 96.8 (92.7 to 99.0) | 96.8 (92.6 to 98.9) |
| Serotype 7F (n=159,160) | 100.0 (97.7 to 100.0) | 100.0 (97.7 to 100.0) |
| Serotype 9V (n=158,160) | 79.7 (72.6 to 85.7) | 75.0 (67.6 to 81.5) |
| Serotype 14 (n=157,160) | 81.5 (74.6 to 87.3) | 89.4 (83.5 to 93.7) |
| Serotype 18C (n=159,160) | 99.4 (96.5 to 100.0) | 99.4 (96.6 to 100.0) |
| Serotype 19A (n=160,160) | 95.6 (91.2 to 98.2) | 97.5 (93.7 to 99.3) |
| Serotype 19F (n=158,159) | 93.7 (88.7 to 96.9) | 94.3 (89.5 to 97.4) |
| Serotype 23F (n=159,160) | 96.2 (92.0 to 98.6) | 97.5 (93.7 to 99.3) |
Antibody geometric mean titers as measured by OPA assay for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMTs were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. Here "n"= participants evaluable =specified category.
| titer | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) |
|---|---|---|
| Serotype 1 (n=159,160) | 48 (39.0 to 58.0) | 52 (43.2 to 62.6) |
| Serotype 3 (n=160,160) | 97 (87.3 to 108.8) | 122 (110.1 to 135.7) |
| Serotype 4 (n=159,159) | 1666 (1412.3 to 1966.3) | 1492 (1285.2 to 1732.3) |
| Serotype 5 (n=160,159) | 79 (67.7 to 92.4) | 80 (69.1 to 92.6) |
| Serotype 6A (n=160,160) | 1690 (1460.5 to 1955.9) | 1968 (1698.5 to 2279.3) |
| Serotype 6B (n=156,155) | 1990 (1611.7 to 2456.9) | 2014 (1639.1 to 2475.4) |
| Serotype 7F (n=159,160) | 2891 (2565.4 to 3258.5) | 3450 (3014.7 to 3947.9) |
| Serotype 9V (n=158,160) | 709 (600.5 to 836.2) | 706 (597.0 to 835.3) |
| Serotype 14 (n=157,160) | 567 (415.4 to 773.5) | 786 (607.8 to 1015.3) |
| Serotype 18C (n=159,160) | 2792 (2387.5 to 3264.8) | 1605 (1352.0 to 1904.4) |
| Serotype 19A (n=160,160) | 305 (256.2 to 362.9) | 329 (284.8 to 379.8) |
| Serotype 19F (n=158,159) | 430 (357.6 to 517.1) | 470 (391.4 to 565.3) |
| Serotype 23F (n=159,160) | 918 (729.0 to 1156.4) | 998 (810.6 to 1229.6) |
Collected over Adverse events (AEs)/serious AEs (SAEs): recorded from signing of informed consent form to 28 to 42 days after dose 3. Pre-specified AEs were recorded in an electronic diary: local reactions, systemic events (Day 2 to Day 6 after each vaccination). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC MDV: Informed Consent to Dose 1 | — | 0/250 (0%) | 2/250 (0.8%) |
| 13vPnC SDS: Informed Consent to Dose 1 | — | 0/250 (0%) | 0/250 (0%) |
| 13vPnC MDV: After Dose 1 | — | 0/250 (0%) | 113/250 (45.2%) |
| 13vPnC SDS: After Dose 1 | — | 0/250 (0%) | 107/250 (42.8%) |
| 13vPnC MDV: After Dose 2 | — | 0/249 (0%) | 114/249 (45.8%) |
| 13vPnC SDS: After Dose 2 | — | 0/248 (0%) | 99/248 (39.9%) |
| 13vPnC MDV: After Dose 3 | — | 1/247 (0.4%) | 97/247 (39.3%) |
| 13vPnC SDS: After Dose 3 | — | 0/244 (0%) | 102/244 (41.8%) |
| Screened Only | — | 0/26 (0%) | 9/26 (34.6%) |
| Event | 13vPnC MDV: Informed Consent to Dose 1 | 13vPnC SDS: Informed Consent to Dose 1 | 13vPnC MDV: After Dose 1 | 13vPnC SDS: After Dose 1 | 13vPnC MDV: After Dose 2 | 13vPnC SDS: After Dose 2 | 13vPnC MDV: After Dose 3 | 13vPnC SDS: After Dose 3 | Screened Only |
|---|---|---|---|---|---|---|---|---|---|
| Sudden infant death syndromeGeneral disorders | 0/250 | 0/250 | 0/250 | 0/250 | 0/249 | 0/248 | 1/247 | 0/244 | 0/26 |
| Event | 13vPnC MDV: Informed Consent to Dose 1 | 13vPnC SDS: Informed Consent to Dose 1 | 13vPnC MDV: After Dose 1 | 13vPnC SDS: After Dose 1 | 13vPnC MDV: After Dose 2 | 13vPnC SDS: After Dose 2 | 13vPnC MDV: After Dose 3 | 13vPnC SDS: After Dose 3 | Screened Only |
|---|---|---|---|---|---|---|---|---|---|
| Irritability: AnyGeneral disorders | — | — | 103/249 | 93/250 | 93/248 | 83/247 | 83/246 | 92/243 | 0/26 |
| Irritability: MildGeneral disorders | — | — | 86/249 | 77/250 | 75/248 | 67/247 | 71/246 | 74/242 | 0/26 |
| Tenderness: AnySkin and subcutaneous tissue disorders | — | — | 42/248 | 47/250 | 34/248 | 32/247 | 37/246 | 35/241 | 0/26 |
| Tenderness: MildSkin and subcutaneous tissue disorders | — | — | 32/248 | 37/250 | 27/248 | 28/247 | 30/246 | 32/241 | 0/26 |
| Failure to thriveMetabolism and nutrition disorders | 0/250 | 0/250 | 0/250 | 0/250 | 0/249 | 0/248 | 0/247 | 1/244 | 3/26 |
| Decreased appetite: AnyGeneral disorders | — | — | 17/248 | 26/250 | 28/247 | 18/247 | 24/246 | 20/242 | 0/26 |
| Decreased appetite: ModerateGeneral disorders | — | — | 17/248 | 26/250 | 28/247 | 18/247 | 24/246 | 19/242 | 0/26 |
| Upper respiratory tract infectionInfections and infestations | 1/250 | 0/250 | 27/250 | 17/250 | 17/249 | 10/248 | 19/247 | 25/244 | 0/26 |
| Increased sleep: AnyGeneral disorders | — | — | 16/248 | 14/250 | 24/247 | 14/247 | 12/246 | 12/241 | 0/26 |
| Irritability: ModerateGeneral disorders | — | — | 19/248 | 17/250 | 23/247 | 17/247 | 15/246 | 18/242 | 0/26 |
Safety population included all participants who received at least 1 dose of investigational product.
| Age, Continuous(days) | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) | Total |
|---|---|---|---|
| Mean | 57.3 ± 8.6 | 56.9 ± 8.8 | 57.1 ± 8.7 |
| Sex: Female, Male(Participants) | 13vPnC Multi-dose Vial (MDV) | 13vPnC Single-Dose Syringe (SDS) | Total |
|---|---|---|---|
| Female | 129 | 130 | 259 |
| Male | 121 | 120 | 241 |
The record gives a start of Jan 2014, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine